

# Understanding consumer receptivity towards foods and non-prescription pills containing phytosterols as a means to offset the risk of cardiovascular disease: an application of protection motivation theory

Spencer Henson, John Cranfield and Deepananda Herath

Department of Food, Agricultural and Resource Economics, University of Guelph, Guelph, ON, Canada

## Keywords

Functional foods, nutraceuticals, protection motivation theory, cardiovascular disease, structural equation modelling.

## Correspondence

Spencer Henson, Department of Food, Agricultural and Resource Economics, University of Guelph, Guelph, ON N1G 2W1, Canada.

E-mail: shenson@uoguelph.ca

doi: 10.1111/j.1470-6431.2009.00829.x

## Abstract

Consumer purchase intention with respect to foods and non-prescription pills containing phytosterols was investigated through a mall intercept survey ( $n = 446$ ) in Ontario, Canada. The study took as its starting point the Protection Motivation Theory (PMT), a social cognition model rooted in research on fear appeal in determining health-protective behaviour. Structural equation modelling was used to explore whether an adaptation of PMT explains intention to purchase products containing phytosterols as a means to reduce the risk of cardiovascular disease (CVD). The standard form of PMT was adapted to take account of consumer perceptions of the risk of elevated blood cholesterol, reflecting the fact that phytosterols do not directly reduce the risk of CVD but rather help in the management of a single risk factor. Overall, coping appraisal had a positive and significant association with purchase intention, while threat appraisal had no significant effect. Incorporation of cholesterol as a risk factor for CVD significantly improved the measurement strength of the threat appraisal construct. However, the overall predictive power of the model did not change appreciably. The results suggest that the promotion of adaptive behaviours, such as consumption of functional foods and nutraceuticals, needs to focus on perception of response and self-efficacy rather than individual perceptions of risk.

## Introduction

Worldwide, cardiovascular disease (CVD) is the leading cause of death and a major cause of disability and lost productivity (Lopez *et al.*, 2006). A multitude of risk factors are associated with CVD, including tobacco smoking, hypertension and diabetes mellitus, with the most important diet-related risk factor being the level and composition of serum cholesterol (American Heart Association, 1998). Indeed, there is compelling evidence that the risk of CVD can be decreased appreciably through the lowering of total and low-density lipoprotein (LDL) cholesterol (Journal of American Medical Association, 2001), with dietary habits being a critical modifiable factor contributing towards this reduction (Keys *et al.*, 1986; Journal of American Medical Association, 2001).

Recently, the role of functional foods and nutraceuticals as a potential means to reduce the risk of certain non-communicable and diet-related diseases has been recognized (see, for example, American Dietetic Association, 2004; Arnoldi, 2004; Institute of Food Technologists, 2005; Rudkowska and Jones, 2007). Diplock *et al.* (1999, p. 16) note:

A food can be regarded as 'functional' if it is satisfactorily demonstrated to affect beneficially one or more target functions in the body, beyond adequate nutritional effects, in a way that is relevant to either an improved state of health and wellbeing and/or reduction of risk of disease.

Indeed, market sales of functional foods and nutraceuticals have registered significant rates of growth since the late 1990s, such that global sales were estimated at around US\$85 billion in 2006 (Nutrition Business Journal, 2007). Of this global total, most sales are in industrialized countries, especially Japan, the US, Europe and Canada.

A notable functional food and nutraceutical innovation associated with reductions in blood cholesterol is the incorporation of plant sterols and stanols (phytosterols) into foods, such as vegetable oil spreads and dairy drinks, and non-prescription pills (Law, 2000; Ntanios, 2001; Rudkowska and Jones, 2007). Phytosterols are chemically similar to cholesterol and, when consumed at adequate levels, can inhibit exogenous and endogenous cholesterol in the gastrointestinal tract (Maki *et al.*, 2003). A number of human clinical trials (see, for example, Weststrate and Meijer, 1998; Hendriks, 1999; Jones *et al.*, 1999; Maki

*et al.*, 2003) have demonstrated that regular consumption of phytosterols can lower total and LDL cholesterol (see reviews by Ling and Jones, 1995; Law, 2000; Rudkowska and Jones, 2007), and thereby decrease the risk of CVD. The report of the US National Cholesterol Education Program Adult Treatment Panel-III enunciates 'therapeutic lifestyle changes' for reducing LDL, in which weight reduction, increased physical activity and reduced intakes of saturated fats are key in the initial stages. In the event that such lifestyle changes are not effective in achieving target LDL levels, the report recommends intake of phytosterols and soluble fibre.

Significant potential public health and economic benefits from consumption of food products and/or non-prescription pills containing phytosterols (see, for example, Malla *et al.*, 2005; Gerber *et al.*, 2006) have been estimated, although the realization of these benefits is dependent on the propensity of consumers to make commensurate changes in their diets. Indeed, the importance of understanding consumer perceptions of functional foods and nutraceuticals, alongside other food technologies, has been recognized (see, for example, Wruck, 1993; Childs and Poryzees, 1997; Gilbert, 2000; Frewer *et al.*, 2003; Verbeke, 2005; Niva, 2007; Blandon *et al.*, 2008; Herath *et al.*, 2008).

A sizeable empirical research literature on consumer attitudes towards functional foods and nutraceuticals has been established (see, for example, Bech-Larsen *et al.*, 2001; Heasman and Mellett, 2001; West *et al.*, 2002; DeJong *et al.*, 2003; Cox *et al.*, 2004; Lucknow and Delehunty, 2004; Urala and Lahteenmaki, 2004; Sorenson and Bogue, 2005; Verbeke, 2005; Henson *et al.*, 2008). Existing studies suggest that belief in the efficacy of functional ingredients plays a critical role in determining the propensity to consume. However, there is also evidence that, aside from perceived efficacy, the mode through which functional ingredients are delivered mitigates consumer acceptability (DeJong *et al.*, 2003; Wennstrom and Mellentin, 2003; Henson *et al.*, 2008), in part because of variation in perceptions of the ability to use such products effectively (Cox *et al.*, 2004). It is evident, however, that more research is needed on the propensity of consumers to use functional foods and nutraceuticals as part of broader strategies towards health-related dietary change and how this varies across functional ingredients. Here, we focus specifically on the use of phytosterols and relations with perceptions of impacts on levels of blood cholesterol and, in turn, the personal risk of CVD. More generally, the results address the paucity of studies on consumer acceptance of functional foods and nutraceuticals in Canada (with the notable exceptions of West *et al.*, 2002; Labrecque *et al.*, 2006; Malla *et al.*, 2005; Henson *et al.*, 2008), recognizing that attitudes towards such products tend to be culture specific (Bech-Larsen *et al.*, 2001; Labrecque *et al.*, 2006).

## Modelling consumer propensity to consume food products and non-prescription pills containing phytosterols

Several behavioural theories from social psychology have been used to understand the propensity of individuals to take actions towards health improvement (Armitage and Conner,

2000).<sup>1</sup> Broadly, all of these approaches recognize that the motivation for health protection results from perceived threat and the desire to avoid the associated potential negative outcomes, and that the response of individuals reflects a balancing of the costs and benefits of alternative courses of action (Floyd *et al.*, 2000). Comparing the results of empirical studies using these alternative paradigms is, however, plagued by data problems (Weinstein, 1993, 2007).


The theoretical underpinning of the current study is Protection Motivation Theory (PMT), a social cognition model rooted in research on fear appeal in determining health-protective behaviour (Rogers, 1975; Maddux and Rogers, 1983). PMT has been widely applied in health psychology research (see, for example, Rippetoe and Rogers, 1987; Plotnikoff and Higgingbotham, 1995, 1998; Orbell and Sheeran, 1998; Palardy *et al.*, 1998; Floyd *et al.*, 2000; Milne *et al.*, 2000; Rutter *et al.*, 2003). It has been shown to have good predictive power in the case of health-related dietary change (see, for example, Plotnikoff and Higgingbotham, 1995, 1998; Cranfield *et al.*, 2007) and specifically, with respect to the use of functional foods and nutraceuticals (Cox *et al.*, 2004; Cox and Bastiaans, 2007; Henson *et al.*, 2008).

According to PMT, health-related behaviour results from expected consequences and perceived value, while significant differences exist in perceptions of the ability to influence or control own health across individuals. When faced with a potential threat, an individual first assesses whether that threat applies to them (*threat appraisal*) and then considers alternative preventive behaviours (*coping appraisal*) (Tanner *et al.*, 1989, 1991; Weinstein *et al.*, 1998; Neuwirth *et al.*, 2000) (Fig. 1). Although protection motivation is latent, and so not directly observable, it is indexed by behavioural intention, which is considered a reasonable predictor of behaviour (Ajzen, 1988).

Threat appraisal is the process whereby an individual evaluates the factors that increase or decrease the incentives to take protective actions in the form of behavioural change against a health threat. These behaviours may vary, including changing existing behaviours and/or adopting new ones, according to the nature of the threat, the individual's *vulnerability* to it, and the intrinsic and extrinsic rewards associated with the change in behaviour that closely reflect the *severity* of the disease (Neuwirth *et al.*, 2000). Thus, before changing their behaviour, an individual must conclude that the specific hazard directly affects them and that the effects of the hazard outweigh the benefits of continuing with existing 'undesirable' behaviour.

The perceived threat of the disease stimulates the individual to take coping strategies in order to protect himself/herself from this

<sup>1</sup>Examples include the Health Belief Model (see, for example, Becker *et al.*, 1977; Aho, 1979; O'Connell *et al.*, 1985; Schafer *et al.*, 1995; Sapp and Jensen, 1998; Kloeblen and Batish, 1999; Nejad *et al.*, 2005; Sapp and Weng, 2007), Transtheoretical Model (see, for example, Greene *et al.*, 1999; Howarth, 1999; Burke *et al.*, 2000; Littell and Girvin, 2002; Frenn and Malin, 2003; Clark *et al.*, 2005; Chung *et al.*, 2006; De Vet *et al.*, 2006; Lea *et al.*, 2006; Shepherd, 2006), Social Cognitive Theory (see, for example, Miller *et al.*, 1999; Reynolds *et al.*, 1999; Anderson *et al.*, 2000, 2007; Rinderknecht and Smith, 2004) and Theory of Reasoned Action/Theory of Planned Behaviour (see, for example, Armitage and Conner, 1999; Leek *et al.*, 2000; Sparks *et al.*, 2001; Olsen, 2001; Chase *et al.*, 2003; Lytle *et al.*, 2003; Nejad *et al.*, 2005; Verbeke and Vackier, 2005; Fila and Smith, 2006).



**Figure 1** Major cognitive components of the Protection Motivation Theory.

threat. This coping appraisal process consists of three simultaneous actions: (1) a belief that the preventive behaviour will work (*response efficacy*); (2) an assessment of self-ability to cope with the threat, initiate change from the risky behaviour and complete the adaptive behaviour (*self-efficacy*); and (3) an estimation of the costs associated with the consequent behavioural change (*response cost*) (Gardner and Stern, 1996; Rogers and Prentice-Dunn, 1997). Response efficacy and self-efficacy tend to increase the likelihood of making a behavioural change, while the associated financial cost, and/or time and effort reduces the probability of reacting to a hazard. The relationship between these three elements of coping appraisal is generally considered to be linear and additive (Rogers, 1983).

PMT suggests that an individual confronted with the potential risk of CVD will first assess their own threat based on their awareness and knowledge, current health state and perceived vulnerability. Key here might be the extent to which there is a history of heart health problems in the individual's family. A perceived threat will only lead to behavioural change, however, if the individual believes that they are able to cope with that threat. Causes of continuing maladaptive behaviour can include feelings of defensiveness, hopelessness and/or fatalism, social context or the demand for immediacy of reward (Rogers and Prentice-Dunn, 1997). Consumers may also lack knowledge of potential adaptive behaviours. Having decided to make a behavioural change, the individual must be convinced that the potential course of action will curtail their risk of CVD and/or the severity of effects (*response efficacy*), and that they will be able to follow through with those actions (*self-efficacy*). The combination of a high threat appraisal and high coping appraisal translates into higher protection motivation.

The particular focus of the current study is the propensity of consumers to take actions aimed at mitigating blood cholesterol as a key risk factor for CVD. Although the end result and the rationale for such behaviour is a reduction in the risk of CVD, a variety of other factors might mitigate the change in risk at the level of the individual, whether related to their genetic disposition or because

of offsetting behaviour (for example, reductions in levels of physical exercise and/or increases in levels of tobacco use). This is a quite different context to most other applications of PMT and requires adaptation of the core PMT model. Thus, we incorporate an additional *cholesterol risk* component into the threat appraisal construct that assesses perceptions of the extent to which the single risk factor (blood cholesterol) is associated with the risk of contracting the disease (CVD). The rationale behind this is that the consumer is unlikely to take a protective action against elevated blood cholesterol, regardless of how great the threat they perceive from CVD, unless they consider blood cholesterol to have a strong association with the perceived vulnerability and/or severity of CVD that they face.

At the same time that blood cholesterol is a risk factor for CVD, it also acts as a 'biomarker' of the threat to the individual (McClure, 2002; Senior and Marteau, 2007). A priori, this might suggest that, in the context of CVD, the risk factor component is likely to be a major determinant of the threat appraisal construct. However, evidence that biomarker feedback increases the motivation to change behaviour tends to be quite weak (see, for example, McClure, 2002). In the case of blood cholesterol specifically, while some studies indicate that individuals provided with information on their cholesterol risk profile exhibit a greater intent to make dietary changes compared with control groups (Gemson *et al.*, 1990; Aubin *et al.*, 1998), other studies report that consumers with or without their cholesterol risk profile are equally likely to change their dietary behaviour in response to nutrition information (Strychar *et al.*, 1998). Further, Robertson *et al.* (1992) and Elton *et al.* (1994) find that providing information on blood cholesterol levels does not significantly lower measurements of post-test cholesterol levels relative to individuals that do not receive such information.

## Methods

The data collection instrument was designed to investigate the propensity of consumers to consume a range of functional ingredients in the form of foods and/or prescription pills, guided by previous literature on the application of PMT to health-related dietary change (Plotnikoff and Higginbottam, 1995, 1998, 2002; Bennett *et al.*, 1998; Milne and Orbell, 2000). The instrument took the form of a structured self-completion questionnaire that included items to capture the theoretical constructs of PMT, including the additional risk factor construct described above. The phrasing of questions and some wider attitudinal elements of the instrument were designed on the basis of a series of four focus groups held over the period of March 2006 to April 2006 in Guelph, Ontario, Canada. The initial version of the questionnaire was pre-tested with 10 recruited consumers, and based on their feedback, a revised and final version was prepared.

The questionnaire was elicited in a shopping mall in Guelph, Ontario, during February 2008. Potential respondents were approached at random and asked if they would be willing to participate in the study. Quotas were applied to the composition of the sample on the basis of age and gender according to the 2001 Canadian census. A total of 446 respondents were surveyed aged 18 years and over. The sample was approximately representative of the Canadian population across most key demographic characteristics (Table 1), with the exception of the 55 years and older age

**Table 1** Characteristics of the study sample compared with the Canadian population

| Characteristics                       | Sample survey     | Canadian population |
|---------------------------------------|-------------------|---------------------|
|                                       | ( <i>n</i> = 446) |                     |
|                                       | <i>n</i> (%)      | %                   |
| Gender                                |                   |                     |
| Male                                  | 221 (49.6)        | 48.9                |
| Female                                | 225 (50.4)        | 51.0                |
| Age                                   |                   |                     |
| 18–34                                 | 144 (32.3)        | 26.0                |
| 35–54                                 | 115 (25.8)        | 31.0                |
| 55 and over                           | 187 (42.0)        | 25.3                |
| Education                             |                   |                     |
| Some grade school                     | 28 (6.7)          | N/A                 |
| Some high school/high school graduate | 91 (20.9)         | 23.0                |
| Some university/college               | 116 (23.3)        | 13.4                |
| University/college graduate           | 147 (32.8)        | 25.6                |
| Postgraduate                          | 84 (16.3)         | 4.8                 |
| Total household income                |                   |                     |
| Under \$35 000                        | 109 (24.4)        | 19.7                |
| Above \$35 000 and below \$75 000     | 180 (40.4)        | 41.5                |
| Above \$75 000 and below \$119 000    | 96 (21.6)         | 24.0*               |
| Equal or above \$120 000              | 61 (13.6)         | 14.7**              |

N/A, not applicable.

Note: Information sources for Canadian population as follows:

Gender (2005): Statistics Canada CANSIM II Table 1095315

Age (2006): Statistics Canada 2006 Census

Education (2006): Statistics Canada 2006 Census

Total household Income (2006): Statistics Canada 2006 Census (Note:

\*above \$75 000 and below \$125 000; \*\*\$125 000 and above).

group, and individuals with ‘some university/college’, both of which were oversampled.

### Construction of scales for measurement of PMT variables

Multi-item scales were used to derive measures for each of the PMT model constructs, including the additional cholesterol risk factor construct. In each case, seven-point Likert scales were used to elicit responses. The specific items associated with each construct, their mean values and standard deviation (SD), and the Cronbach alpha coefficients of item reliability are reported in Tables 2 and 3.

Perception of the severity of CVD was captured using five statements where the response options ranged from ‘completely agree’ (7) to ‘completely disagree’ (1). These statements captured the perceived impact of CVD on the respondent’s quality of life, career and financial status (Milne and Orbell, 2000). The Cronbach alpha ( $\alpha = 0.84$ ) indicates that the summated scale is a reliable measure. With an average summated scale score of 4.81 (SD = 1.48), the sample as a whole clearly considered CVD to be relatively severe.

The degree of perceived vulnerability to CVD was assessed using four statements. The first two statements, ‘the risk of heart disease worries me a lot’ and ‘I know many people who have

suffered from heart disease’, were elicited using a scale from ‘completely agree’ (7) to ‘completely disagree’ (1). Two other statements solicited judgements of own risk of CVD compared with the average adult in the Canadian population using a scale ranging from ‘extremely high’ (7) to ‘extremely low’ (1). Recognizing the need to differentiate the risk perceptions of respondents who had already been diagnosed with CVD from those that had not been diagnosed, the statements were phrased differently for each subgroup (see part I and part II under the vulnerability construct in Table 2). Overall, the multi-item scale measuring the vulnerability construct had acceptable reliability ( $\alpha = 0.59$ ) that is broadly comparable to previous studies (for example, Plotnikoff and Higginbotham, 1995). The sample average of the summated scale (3.71; SD = 1.32) suggested that the overall level of perceived vulnerability was low, especially relative to perceived severity.

The additional construct to incorporate perceptions of cholesterol as a risk factor for CVD (*cholesterol risk*) was based on a three-item scale. The first two statements, ‘failure to control your blood cholesterol puts you at a greater risk of getting heart disease’ and ‘blood cholesterol is a major factor for heart disease’, were scored on a scale ranging from ‘completely agree’ (7) to ‘completely disagree’ (1). The third statement judged respondent’s perception of the importance of controlling blood cholesterol in determining his/her own risk of developing CVD from ‘extremely important’ (7) to ‘extremely unimportant’ (1). The reliability of the multi-item scale was very good ( $\alpha = 0.84$ ). The mean value of the scale was high at 5.71 (SD = 1.11), suggesting strong perceptions that cholesterol is a risk factor for CVD.

The concurrent validity of the summated scale for cholesterol risk was assessed by comparing the mean value of respondents according to their serum cholesterol testing. It was hypothesized that respondents who had not recently had their blood cholesterol tested (specifically, in the last 6 years) (group 1) would perceive a weaker association between blood cholesterol and the risk of CVD compared with respondents who had recently had their blood cholesterol tested (specifically, in the last 2 years) (group 2). This was confirmed by the average values of the summated scales for cholesterol risk, which were 5.24 (SD = 0.85) for group 2 and 4.96 (SD = 0.96) for group 1. This difference was statistically significant ( $P = 0.005$ ) and suggests that the cholesterol risk construct indeed exhibited concurrent validity.

The response efficacy of consuming food products and non-prescription pills containing phytosterols as a means to control blood cholesterol was captured through perceptions of the effectiveness of four alternative products (namely, a non-prescription pill, margarine, low-fat milk and bread) on a scale from ‘completely agree’ (7) to ‘completely disagree’ (1) (Table 3). The sample average of the perceived effectiveness of bread containing phytosterols at controlling blood cholesterol (4.63; SD = 1.89) was significantly ( $P < 0.000$ ) higher than for the non-prescription pill (4.13; SD = 1.97) and margarine (4.20; SD = 1.95), but not significantly different from the low-fat milk (4.57; SD = 1.95). The average of the perceived effectiveness of these four modes of delivery was used as a construct representing the response efficacy of phytosterols overall. The reliability of the multi-item scale for response efficacy of phytosterols was very good ( $\alpha = 0.87$ ). The average value of the multi-item scale was 4.38 (SD = 1.63).

**Table 2** Basic statistics on threat appraisal constructs for path model

| Threat appraisal constructs/items  | Mean | SD   |
|--|------|------|
| <b>Severity (completely agree = 7; completely disagree = 1)</b>  |      |      |
| My quality of life would be severely affected by heart disease   | 5.81 | 1.30 |
| Having heart disease would seriously affect my career  | 4.46 | 2.14 |
| Having heart disease would reduce my quality of life significantly   | 5.30 | 1.71 |
| Having heart disease would seriously affect my financial situation   | 4.40 | 2.01 |
| Having heart disease would slow/halt my career advancement   |      |      |
| Summated scale for severity ( $\alpha = 0.8345$ )  | 4.81 | 1.48 |
| <b>Vulnerability</b>   |      |      |
| The risk of heart disease worries me a lot (completely agree = 7; completely disagree = 1)   | 3.44 | 1.80 |
| I know many people who have suffered from heart diseases (completely agree = 7; completely disagree = 1)   | 4.09 | 1.95 |
| <b>For respondents who has not been diagnosed with heart diseases</b>  |      |      |
| Compared with the average adult Canadian of my gender, my risk of developing heart disease is . . . (extremely high = 7; extremely low = 1)  | 3.68 | 1.61 |
| I believe that the likelihood that I will have heart disease in the future is . . . (extremely high = 7; extremely low = 1)  | 3.51 | 1.53 |
| <b>For respondents who has been diagnosed with heart diseases</b>  |      |      |
| Looking back to the time before the diagnosis, please recall your perception of your risk of developing heart disease when compared with the average adult Canadian of your gender. Was this . . . (extremely high = 7; extremely low = 1) | 4.08 | 1.80 |
| Again, looking back to that time, please recall your belief of the likelihood that you would have heart disease in the future. Was this . . . (extremely high = 7; extremely low = 1)  | 4.2  | 1.93 |
| Summated scale for vulnerability ( $\alpha = 0.5911$ )   | 3.71 | 1.32 |
| <b>Cholesterol risk</b>  |      |      |
| Failure to control your blood cholesterol puts you at greater risk of getting heart disease (completely agree = 7; completely disagree = 1)  | 5.65 | 1.46 |
| Blood cholesterol is a major risk factor for heart diseases (completely agree = 7; completely disagree = 1)  | 5.33 | 1.49 |
| Importance of controlling blood cholesterol in determining own risk of developing heart disease (extremely important = 7; extremely unimportant = 1)   | 6.13 | 1.17 |
| Summated scale for cholesterol risk ( $\alpha = 0.8378$ )  | 5.71 | 1.11 |

SD, standard deviation.


| Coping appraisal   | Mean | SD   |
|--|------|------|
| <b>Response efficacy</b>   |      |      |
| Following products are effective ways to reduce blood cholesterol for you personally (completely agree = 7; completely disagree = 1)   |      |      |
| A non-prescription pill containing phytosterols  | 4.13 | 1.97 |
| Margarine containing phytosterols  | 4.20 | 1.95 |
| Low-fat milk containing phytosterols   | 4.57 | 1.95 |
| Bread containing phytosterols  | 4.63 | 1.82 |
| Summated scale for response efficacy ( $\alpha = 0.8680$ )   | 4.38 | 1.63 |
| <b>Self-efficacy</b>   |      |      |
| How confident are you personally in your ability and inclination to consume the recommended quantities of each of the following products to reduce your own blood cholesterol effectively (extremely confident = 7; extremely unconfident = 1) |      |      |
| A non-prescription pill containing phytosterols  | 3.85 | 2.09 |
| Margarine containing phytosterols  | 4.09 | 2.12 |
| Low-fat milk containing phytosterols   | 4.39 | 2.10 |
| Bread containing phytosterols  | 4.51 | 1.99 |
| Summated scale for self-efficacy ( $\alpha = 0.8740$ )   | 4.19 | 1.76 |

SD, standard deviation.

**Table 3** Basic statistics on coping appraisal constructs for path model

The self-efficacy of consuming each of the four phytosterol-containing products was assessed through a single item for each, ‘please tell me how confident are you personally in your ability to consume the recommended quantities of each of the following

products to reduce your own blood cholesterol effectively’, using a scale from ‘extremely confident’ (7) to ‘extremely unconfident’ (1). Overall, respondents were least confident in their ability to use the non-prescription pill (3.85; SD = 2.09) and most confident in



**Figure 2** Path diagram of the structural equation model of the Protection Motivation Theory constructs.

the self-efficacy of bread (4.51; SD = 1.99). As with response efficacy, a single measure of self-efficacy was derived by taking the average value of perceived self-efficacy across the four modes of delivery. The reliability of the multi-item scale for self-efficacy was very good ( $\alpha = 0.87$ ). The average value of the multi-item scale was 4.19 (SD = 1.76).

Behavioural intention in terms of consumption of each of the four phytosterol-containing products was evaluated through a single item, 'please tell me how likely you would be to purchase the product to reduce your own level of blood cholesterol', using a scale from 'very likely' (7) to 'very unlikely' (1). A single measure of behavioural intention was constructed from the average across the four modes of delivery. The reliability of the multi-item scale was very good ( $\alpha = 0.84$ ). The average value of the multi-item scale was 3.94 (SD = 1.79).

## Results

Following the standard form of PMT, behavioural intention was modelled as a linear function of the threat appraisal and coping appraisal latent constructs (Fig. 2). Specifically, structural equation modelling was used to capture linear relationships between the latent constructs and the relevant reflective indicators: between threat appraisal and the indicators' perceived severity, perceived vulnerability and perceived cholesterol risk, and between coping appraisal and the indicators' perceived response efficacy and perceived self-efficacy. The two latent constructs were hypothesized to be linearly related to the formative indicator of purchase intention. The model was estimated using LISREL 8.8 version (Scientific Software International, Inc. Lincolnwood, IL, US) (Joreskog and Sorbon, 1999). The errors of the measurement models capturing directional association between the reflective indicators and the latent threat and coping appraisal constructs were designated as  $\delta$ s. The error of the structural model linking threat and coping appraisal with behavioural intention were designated as  $\varepsilon$  (Fig. 2).

PMT was first applied to the intention to purchase food products and/or non-prescription pills containing phytosterols as a means to manage blood cholesterol in its standard form (i.e. without the cholesterol risk construct) (model I). Subsequently, cholesterol risk was introduced as an additional formative variable on the threat appraisal latent construct (model II). The results for these two models are reported in Table 4.

The overall fit of model I is impressive [ $\chi^2 = 4.19$ ; degrees of freedom ( $df$ ) = 3;  $P = 0.24$ ; root mean square error of approximation (RMSEA) = 0.030]; a RMSEA below 0.05 is indicative of acceptable fit of the data (Diamantopoulos and Sigauw, 2000). In model II, the overall model fit was acceptable, although the introduction of the cholesterol risk construct did not provide an appreciable improvement ( $\chi^2 = 11.65$ ;  $df = 7$ ;  $P = 0.11$ ; RMSEA = 0.039). The 90% confidence interval for RMSEA (0.0–0.09) was clearly within the acceptable region (Diamantopoulos and Sigauw, 2000). Further, the strength of the positive associations between the threat appraisal construct and the severity and vulnerability constructs was significantly greater.

### Testing the measurement model: threat appraisal

The measurement model between threat appraisal and the severity and vulnerability formative variables in model I revealed substantial measurement errors. As indicated by the  $R$ -square values, only 9% of variation in the severity construct and 21% of variation in the vulnerability construct were explained by the threat appraisal latent variable. Despite such measurement errors,  $t$ -values for the threat appraisal latent construct were significant ( $P < 0.000$ ) for both the severity and vulnerability constructs, suggesting that these formative variables are appropriate. As expected, the cholesterol risk construct had a pronounced directional linkage with the threat appraisal latent construct. In model II, around 52% of variability in cholesterol risk was explained by threat appraisal. The incorporation of the cholesterol risk construct also led to improved convergent validity in terms of  $t$ -values and  $R$ -square values for both the severity ( $R$ -square increased from 0.09 to 0.15) and vulnerability ( $R$ -square increased from 0.21 to 0.29) variables (Table 4). As indicated by the standardized coefficients, among the three formative variables for threat appraisal, cholesterol risk had the greatest impact (0.86) and was the strongest predictor.

The composite (construct) reliability<sup>2</sup> of the three individual formative indicators in measuring the threat appraisal latent construct was calculated based on the completely standardized LISREL solution (Diamantopoulos and Sigauw, 2000). It is suggested in the literature that a composite reliability ( $\rho_c$ ) value exceeding 0.6 is desirable (Bagozzi and Yi, 1988). In model II, the  $\rho_c$  value for the threat appraisal construct was 0.52, suggesting that the three formative variables provided an acceptable level of composite reliability.

### Testing the measurement model: coping appraisal

In model I, the level of measurement errors in the relationships between the latent coping appraisal variable and associated formative variables for self-efficacy and response efficacy were much lower than for threat appraisal, with  $R$ -square values of 0.73 and

$$\rho_c = \frac{(\sum \lambda)^2}{[(\sum \lambda)^2 + \sum \theta]}$$

where  $\rho_c$  = composite reliability,  $\lambda$  = formative indicator loading and  $\theta$  = formative indicator error variance.

**Table 4** Estimates of path coefficients for the Protection Motivation Theory model

| Model/variable                     | Label         | Coefficient<br>( <i>t</i> -value) | Standardized<br>coefficient | <i>R</i> <sup>2</sup> | Label                               | Coefficient<br>( <i>t</i> -value) | Standardized<br>coefficient | <i>R</i> <sup>2</sup> |
|------------------------------------|---------------|-----------------------------------|-----------------------------|-----------------------|-------------------------------------|-----------------------------------|-----------------------------|-----------------------|
| Model I (without cholesterol risk) |               |                                   |                             |                       | Model II (with cholesterol risk)    |                                   |                             |                       |
| Threat appraisal                   |               |                                   |                             |                       |                                     |                                   |                             |                       |
| Severity                           | $\gamma_{11}$ | 0.48 (4.13***)                    | 0.26                        | 0.09                  | $\gamma_{11}$                       | 0.59 (6.37***)                    | 0.33                        | 0.15                  |
| Vulnerability                      | $\gamma_{12}$ | 0.62 (4.70***)                    | 0.41                        | 0.21                  | $\gamma_{12}$                       | 0.73 (8.51***)                    | 0.52                        | 0.29                  |
| Cholesterol risk                   | –             | –                                 | –                           | –                     | $\gamma_{13}$                       | 0.86 (10.80***)                   | 0.67                        | 0.52                  |
| Coping appraisal                   |               |                                   |                             |                       |                                     |                                   |                             |                       |
| Self-efficacy                      | $\gamma_{21}$ | 1.52 (21.17***)                   | 0.85                        | 0.73                  | $\gamma_{21}$                       | 1.52 (17.74***)                   | 0.89                        | 0.72                  |
| Response efficacy                  | $\gamma_{22}$ | 1.41 (21.11***)                   | 0.85                        | 0.73                  | $\gamma_{22}$                       | 1.41 (21.29***)                   | 0.85                        | 0.73                  |
| Model I – structural relationships |               |                                   |                             |                       | Model II – structural relationships |                                   |                             |                       |
| Threat appraisal                   | $\beta_{11}$  | –0.11 (–0.55)                     | –0.005                      | 0.76                  | $\beta_{11}$                        | –0.068 (–0.77)                    | –0.07                       | 0.76                  |
| Coping appraisal                   | $\beta_{21}$  | 1.65 (10.41***)                   | 0.77                        |                       | $\beta_{21}$                        | 1.61 (18.23***)                   | 0.87                        |                       |

The asterisks (\*\*\*) indicate statistically significant at the 1% level.

0.73 respectively (Table 4). The incorporation of the cholesterol risk construct did not improve the directional linkages between coping appraisal, self-efficacy and response efficacy. Indeed, the values of the standardized coefficients for self-efficacy and response efficacy were very similar across models I and II.

As in many other applications of PMT to health protection behaviour (see, for example, Floyd *et al.*, 2000; Milne *et al.*, 2000), the self-efficacy construct had the greatest impact on the coping appraisal latent variable, with a standardized coefficient of 0.85 in model I and 0.85 in model II. The composite (construct) reliability measure of  $\rho_c$  for the two formative indicators in measuring coping appraisal was 0.78, suggesting much better composite construct reliability than for the threat appraisal construct.

### Testing the structural model

As previously noted, many of the overall fit indices for model II suggested appreciable correspondence between the suggested theoretical model and the empirical data (Goodness of Fit = 0.97; Normed Fit Index = 0.96; critical  $N = 920$ ; standardized Root Mean Square Residual = 0.028) (Bagozzi and Yi, 1988). Around 76% of the variation in purchase intention was explained by the threat and coping appraisal constructs. Unexpectedly, however, threat appraisal had a negative association with the intention to purchase foods and/or non-prescription pills containing phytosterols in both model I and model II, although the coefficients were not statistically significant. As indicated by the standardized coefficients, the negative impact of threat appraisal (–0.03) on behavioural intention was much smaller than the positive impact of coping appraisal (0.88). Further, the *t*-value for coping appraisal in explaining behavioural intention was significant ( $P < 0.000$ ) and had a much larger impact than threat appraisal in both model I and model II. These results are broadly comparable to previous studies using PMT; meta-analyses of such studies by Floyd *et al.* (2000) and Milne *et al.* (2000) indicate that the threat appraisal construct generally has weaker predictive capacity and a smaller impact on behavioural intention than the coping appraisal construct.

### Conclusions

The research results reported above contribute to the growing body of studies that use PMT in order to understand the propensity of consumers to undertake health-related dietary change. Further, it fills a specific gap in the literature relating to use of functional foods and nutraceuticals. Although existing research suggests that consumers may be receptive to the consumption of foods and/or non-prescription pills containing functional ingredients, the majority of studies have not related behavioural intentions to efforts that offset specific health risks (notable exceptions include Cox *et al.*, 2004; Cox and Bastiaans, 2007; Henson *et al.*, 2008). The results confirm that the PMT framework can indeed throw considerable light on the propensity of consumers to undertake health-related dietary changes in general and to consume functional foods and nutraceuticals specifically.

As with prior studies on health-related dietary change more broadly, the results suggest that response efficacy and self-efficacy are key drivers of the intention to consume foods and/or non-prescription pills containing phytosterols as a means to reduce the risk of CVD. Thus, as we might expect, consumers are more likely to use such products if they perceive that they work and that they are able to consume such products in the manner that is required in order to be efficacious. At the same time, however, perceptions of the personal threat of CVD do not appear to have an appreciable impact on behavioural intention. Individuals with a low perceived threat of CVD are as likely to indicate a high willingness to consume products containing phytosterols as individuals with a high perceived threat. Taken as a whole, these results suggest that consumers with a high response efficacy are most likely to use products containing phytosterols, regardless of the degree to which they perceive themselves to be at threat from CVD.

Unexpectedly, the inclusion in the analysis of cholesterol as a risk factor for CVD has no appreciable impact on the intention to purchase food and/or non-prescription pills containing phytosterols. This reflects the more general observation that threat appraisal is not a significant driver of behavioural intention. However, at the same time, it suggests that biomarkers, such as

blood cholesterol, that provide a more visible and measurable indicator of risk do not have an appreciable impact on the propensity to undertake adaptive behaviours, in this case, consuming products containing functional ingredients. Alongside the existing literature, these results raise doubts over the extent to which biomarkers more broadly are effective at inducing behavioural change.

The results have significant implications for the promotion of functional foods and nutraceuticals as a part of broader strategies to reduce the incidence of CVD and other non-communicable diseases. A focus on highlighting personal risk of CVD is unlikely to have much success at stimulating consumers to undertake adaptive behaviour. Rather, communication efforts need to focus on evidence that products containing functional ingredients actually reduce personal risk (however great or small that risk might be) and can easily be used in a manner that is efficacious. Such efforts can be undertaken at the population level, with little appreciable benefit being evident from targeting high-risk individuals and/or that high-risk individuals require distinct messaging. At the same time, attention needs to be given to the type and form of products in which functional ingredients are delivered; consumers must be presented with these ingredients in a manner that they perceived to be easy to use, such that the desired level of the functional ingredient is delivered. The results suggest that the perceived effectiveness of phytosterols differs appreciably according to the product in which they are incorporated. The 'bottom line' is that functional ingredients must not only be perceived to work, but be delivered in a form that consumers consider appropriate.

## References

- Aho, W.R. (1979) Smoking, dieting and exercise: age differences in attitudes and behaviour relevant to selected health belief model variables. *Rhode Island Medical Journal*, **62**, 95–102.
- Ajzen, I. (1988) *Attitudes, Personality and Behaviour*. Open University Press, Milton Keynes, UK.
- American Dietetic Association (2004) Position of the American Dietetic Association: functional foods. *Journal of the American Dietetic Association*, **104**, 814–826.
- American Heart Association (1998) Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. *Circulation: Journal of the American Heart Association*, **97**, 1876–1887.
- Anderson, E.S., Winett, R.A. & Wojick, J.R. (2000) Social cognitive determinants of nutrition behaviour among supermarket shoppers: a structural equation analysis. *Health Psychology*, **19**, 479–486.
- Anderson, E.S., Winett, R.A. & Wojicik, J.R. (2007) Self-regulation, self-efficacy, outcome expectations and social support: social cognitive theory and nutrition behaviour. *Annals of Behavioral Medicine*, **34**, 304–312.
- Armitage, C. & Conner, M. (1999) Distinguishing perceptions of control from self-efficacy: predicting consumption of a low fat diet using the theory of planned behaviour. *Journal of Applied Social Psychology*, **29**, 72–90.
- Armitage, C. & Conner, M. (2000) Social cognition models and health behaviour: a structured review. *Psychology and Health*, **15**, 173–189.
- Arnoldi, A. (ed.) (2004) *Functional Foods, Cardiovascular Diseases and Diabetes*. CRC Press, Woodhead Publishing Limited, Cambridge, UK.
- Aubin, M., Godin, G., Vezina, L., Maziade, J. & Desharnais, R. (1998) Hypercholesterolemia screening: does knowledge of blood cholesterol level affect dietary fat intake? *Canadian Family Physician*, **44**, 1289–1297.
- Bagozzi, R. & Yi, Y. (1988) On the evaluation of structural equation models. *Journal of the Academy of Marketing Science*, **16**, 74–94.
- Bech-Larsen, T., Grunert, K.G. & Poulsen, J.B. (2001) The acceptance of functional foods in Denmark, Finland and the United States. MAPP Working Paper 73. The Aarhus School of Business, Aarhus.
- Becker, M., Haefner, D. & Miaman, L. (1977) Health belief model in the prediction of dietary compliance: a field experiment. *Journal of Health and Social Behaviour*, **18**, 348–366.
- Bennett, P., Rowe, A. & Katz, D. (1998) Reported adherence with preventive asthma medication: a test of protection motivation theory. *Psychology, Health and Medicine*, **3**, 347–354.
- Blandon, J., Henson, S. & Cranfield, J. (2008) Functional foods and natural health products: a review of contemporary issues. *CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resource*, **51**, 1–11.
- Burke, V., Richards, J., Milligan, R., Beilin, L., Dunbar, D. & Gracy, M. (2000) Stage of change for health-related behaviours in 18 year-old Australians. *Psychology and Health*, **14**, 1061–1075.
- Chase, K., Reicks, M. & Jones, J.M. (2003) Applying the theory of planned behaviour to promotion of whole-grain foods by dietitians. *Journal of the American Dietetic Association*, **103**, 1639–1642.
- Childs, N.M. & Poryzees, G.H. (1997) Foods that help prevent disease: consumer attitude and public policy implications. *Journal of Consumer Marketing*, **14**, 433–447.
- Chung, S., Hoerr, S., Levine, R. & Coleman, G. (2006) Processes underlying young women's decisions to eat fruits and vegetables. *Journal of Human Nutrition and Dietetics*, **19**, 287–298.
- Clark, P., Rossi, J., Greaney, M., Riebe, D., Green, G., Saunders, S., Lees, F. & Nigg, C. (2005) Intervening on exercise and nutrition in older adults. *Journal of Aging and Health*, **17**, 753–778.
- Cox, D.N. & Bastiaans, K. (2007) Understanding Australian consumers' perceptions of selenium and motivations to consume selenium enriched foods. *Food Quality and Preference*, **18**, 66–76.
- Cox, D.N., Koster, A. & Russell, C.G. (2004) Predicting intentions to consume functional foods and supplements to offset memory loss using an adaptation of protection motivation theory. *Appetite*, **43**, 55–64.
- Cranfield, J.A.L., Boecker, A., Hailu, G., Henson, S., Herath, D. & Annou, M. (2007) Demand for food products promoting health and wellness: analysis of the 2004 Canadians' Demand for Food Products Supporting Health and Wellness Survey. International Food Economy Group Working Paper 01\_DH, Department of Food, Agricultural and Resource Economics, University of Guelph, Canada.
- DeJong, N., Ocke, M.C., Branderhorst, H.A.C. & Friele, R. (2003) Demographic and lifestyle characteristics of functional food consumers and dietary supplement users. *British Journal of Nutrition*, **89**, 55–64.
- De Vet, E., de Nooijer, J., de Vries, N.K. & Bung, J. (2006) The trans-theoretical model for fruit, vegetable and fish consumption: associations between intakes, stages of change and stage of transition determinants. *International Journal of Behavioral Nutrition and Physical Activity*, **3**.
- Diamantopoulos, A. & Sigauw, J.A. (2000) *Introducing Lisrel: A Guide for the Uninitiated*. Sage Publications, London.
- Diplock, A.T., Aggett, P.J., Ashwell, M., Bornet, F., Fern, E.B. & Rob-erfroid, M.B. (1999) Scientific concepts of functional foods in Europe: consensus document. *British Journal of Nutrition*, **81** (suppl. 1), S1–S27.

- Elton, N.H., Hanna, M.M. & Treasure, J. (1994) Coping with chronic pain. Some patients suffer more. *The British Journal of Psychiatry*, **165**, 802–807.
- Fila, S.A. & Smith, C. (2006) Applying the theory of planned behaviour to healthy eating behaviour in urban Native American youth. *International Journal of Behavioural Nutrition and Physical Activity*, **3**, 1–10.
- Floyd, D.L., Prentice-Dunn, S. & Rogers, R.W. (2000) A meta-analysis of protection motivation theory. *Journal of Applied Social Psychology*, **30**, 407–429.
- Frenn, M. & Malin, S. (2003) Diet and exercise in low-income culturally diverse middle school students. *Public Health Nursing*, **22**, 89–97.
- Frewer, L., Scholderer, J. & Lambert, N. (2003) Consumer acceptance of functional foods: issues for the future. *British Food Journal*, **105**, 714–731.
- Gardner, G.T. & Stern, P.C. (1996) *Environmental Problems and Human Behavior*. Allyn and Bacon, Boston.
- Gemson, D.H., Sloan, R.P., Messeri, P. & Goldberg, I.J. (1990) A public health model for cardiovascular risk reduction: impact of cholesterol screening with brief non-physician counselling. *Archives of Internal Medicine*, **150**, 985–989.
- Gerber, A., Evers, T., Haverkamp, H. & Lauterbach, K.W. (2006) Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction. *European Journal of Health Economics*, **7**, 247–254.
- Gilbert, L. (2000) Marketing functional foods: how to reach your target audience. *AgBioForum*, **3**, 20–38.
- Greene, G.W., Rossi, S.R., Rossi, J.S., Velicer, W.F., Fava, J.L. & Prochaska, J.O. (1999) Dietary applications of the stages of change model. *Journal of the American Dietetic Association*, **99**, 673–678.
- Heasman, M. & Melletin, J. (2001) *The Functional Foods Revolution: Healthy People, Healthy Profits?* Earthscan, London.
- Hendriks, H.F.J., Westrate, J.A., van Vliet, T. & Meijer, G.W. (1999) Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. *European Journal of Clinical Nutrition*, **53**, 319–327.
- Henson, S.J., Masakure, O. & Cranfield, J. (2008) The propensity for consumers to offset health risks through the use of functional foods and nutraceuticals: the case of lycopene. *Food Quality and Preference*, **19**, 395–406.
- Herath, D., Cranfield, J. & Henson, S. (2008) Who consumes functional foods and nutraceuticals in Canada? Results of cluster analysis of the 2006 survey of Canadian's Demand for Food Products Supporting Health and Wellness. *Appetite*, **51**, 256–265.
- Howarth, C.C. (1999) Applying the transtheoretical model to eating behaviour change: challenges and opportunities. *Nutrition Research Reviews*, **12**, 281–317.
- Institute of Food Technologists (2005) *Functional foods: opportunities and challenges*. Expert Report of the Institute of Food Technologists on Functional Foods (March, 2005).
- Jones, P.J.H., Ntanos, F.Y., Raeini-Sarjaz, M.R. & Vanstone, C.A. (1999) Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic men. *American Journal of Clinical Nutrition*, **69**, 1144–1150.
- Joreskog, K. & Sorbom, D. (1999) *PRELIS 2: User's Reference Guide*, 3rd edn. Scientific Software International, Lincolnwood, IL, US.
- Journal of American Medical Association (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *Journal of American Medical Association*, **285**, 2486–2497.
- Keys, A., Menotti, A., Karvonen, M.J., Aravanis, C., Blackburn, H., Buzina, R., Djordjevic, B.S., Dontas, A.S. & Fidanza, F. (1986) The diet and 15-year death rate in the seven countries study. *American Journal of Epidemiology*, **124**, 903–915.
- Kloeblen, A. & Batish, S. (1999) Understanding the intention to permanently follow a high folate diet among a sample of low-income pregnant women according to the Health Belief Model. *Health Education Research*, **14**, 327–338.
- Labrecque, J., Doyon, M., Bellavance, F. & Kolodinsky, J. (2006) Acceptance of functional foods: a comparison of French, American, and Canadian consumers. *Canadian Journal of Agricultural Economics*, **54**, 647–661.
- Law, M. (2000) Plant sterol and stanol margarines and health. *British Medical Journal*, **320**, 861–864.
- Lea, E., Crawford, D. & Worsley, A. (2006) Consumers' readiness to eat plant-based diet. *European Journal of Clinical Nutrition*, **60**, 342–351.
- Leek, S., Maddock, S. & Foxall, G. (2000) Situational determinants of fish consumption. *British Food Journal*, **102**, 18–39.
- Ling, W. & Jones, P.J.H. (1995) Dietary phytosterol: a review of metabolism, benefits and side effects. *Life Science*, **57**, 195–206.
- Littell, J.H. & Girvin, H. (2002) Stages of change: a critique. *Behavior Modification*, **26**, 223–273.
- Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T. & Murray, C.J.L. (eds) (2006) *Global Burden of Disease and Risk Factors*. Oxford University Press, New York.
- Lucknow, T. & Delehunty, C. (2004) Consumer acceptance of orange juice containing functional ingredients. *Food Research International*, **37**, 805–814.
- Lytle, L.A., Varnell, S., Murray, D.M., Story, M., Perry, C., Bimbaum, A.S. & Kubrik, M.Y. (2003) Predicting adolescents intakes of fruit and vegetables. *Journal of Nutrition Education*, **35**, 170–178.
- McClure, J. (2002) Are biomarkers useful treatment aids for promoting health behaviour change? An empirical review. *American Journal of Preventive Medicine*, **22**, 200–207.
- Maddux, J.E. & Rogers, R.W. (1983) Protection motivation theory and self-efficacy: a revised theory of fear appeals and attitude change. *Journal of Experimental Sociology and Psychology*, **19**, 469–479.
- Maki, K.C., Shinnick, F., Seeley, M.A., Vieth, P.E., Quinn, L.C., Hallissey, P.J., Temer, A. & Davidson, M.H. (2003) Food products containing free tall oil-based phytosterols and oat  $\beta$ -glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. *Journal of Nutrition*, **133**, 808–813.
- Malla, S., Hobbs, J.E. & Perger, O. (2005) Estimating the healthcare savings from trans fat-free canola in Canada. *Acta Agriculturae Scandinavica Section C*, **2**, 175–184.
- Miller, P.M., Watkins, J.A., Sargent, R.G. & Rickert, E.J. (1999) Self-efficacy in over-weight individuals with binge eating disorder. *Obesity Research*, **7**, 552–555.
- Milne, S. & Orbell, S. (2000) Can protection motivation theory predict breast self-examination? A longitudinal test exploring the role of previous behaviour. In *Understanding and Changing Health Behaviour: From Health Belief to Self-Regulation* (ed. by P. Norman, C. Abraham & M. Conner), pp. 51–71. Harwood Academic Publishers, Amsterdam, The Netherlands.
- Milne, S., Shreeran, P. & Orbell, S. (2000) Prediction and intervention in health related behavior: meta-analytical review of protection motivation theory. *Journal of Applied Social Psychology*, **30**, 106–143.
- Nejad, L.M., Wertheim, E.H. & Greenwood, K.M. (2005) Comparison of the health belief model and the theory of planned behaviour in the prediction of dieting and fasting behaviour. *E-Journal of Applied Psychology: Social Section*, **1**, 63–74.
- Neuwirth, K., Dunwood, S. & Griffin, R.J. (2000) Protection motivation and risk communication. *Risk Analysis*, **20**, 721–734.

- Niva, M. (2007) 'All foods affect health': understanding of functional foods and healthy eating among health-oriented Finnes. *Appetite*, **48**, 384–393.
- Ntanos, F. (2001) Plant sterol-ester-enriched spreads as an example of a new functional food. *European Journal of Lipid Science and Technology*, **103**, 102–106.
- Nutrition Business Journal (2007) The Global Nutrition Industry VI. *Nutrition Business Journal*, **5/6**, 3–47.
- O'Connell, J., Price, J., Roberts, S., Jurs, S. & McKinley, R. (1985) Utilizing the health belief model to predict dieting and exercising behaviour of obese and non-obese adolescents. *Health Education Quarterly*, **12**, 343–351.
- Olsen, S.O. (2001) Consumer involvement in seafood as family meals in Norway: an application of the expectancy-value approach. *Appetite*, **36**, 173–186.
- Orbell, S. & Sheeran, P. (1998) 'Inclined abstainers': a problem for predicting health related behaviour. *British Journal of Social Psychology*, **37**, 151–165.
- Palardy, N., Greening, L., Ott, J., Dolderby, A. & Atchinson, J. (1998) Adolescents' health attitudes and adherence to treatment for insulin dependent diabetes mellitus. *Developmental and Behavioural Paediatrics*, **19**, 31–37.
- Plotnikoff, R.C. & Higgingsbotham, N. (1995) Predicting low-fat diet intentions and behaviors for the prevention of coronary heart disease: an application of protection motivation theory among an Australian population. *Psychology and Health*, **10**, 397–408.
- Plotnikoff, R.C. & Higgingsbotham, N. (1998) Protection motivation theory and the prediction of exercise and low-fat diet behaviors among Australian cardiac patients. *Psychology and Health*, **13**, 411–429.
- Plotnikoff, R.C. & Higgingsbotham, N. (2002) Protection motivation theory and exercise behavior change for the prevention of coronary heart disease in a high risk, Australian representative community sample of adults. *Psychology, Health and Medicine*, **7**, 87–98.
- Reynolds, K.D., Hinton, A.W., Shewchuk, R.M. & Hickey, C.A. (1999) Social cognitive model of fruit and vegetable consumption in elementary school children. *Journal of Nutrition Education*, **31**, 23–30.
- Rinderknecht, K. & Smith, C. (2004) Social cognitive theory in an after-school nutrition intervention for urban Native American youth. *Journal of Nutrition Education and Behaviour*, **36**, 298–304.
- Rippetoe, P.A. & Rogers, R.W. (1987) Effects of components of protection-motivation theory on adaptive and maladaptive coping with a health threat. *Journal of Personal Social Psychology*, **52**, 596–604.
- Robertson, I., Phillips, A., Mant, D., Thorogood, M., Fowler, G., Fuller, A., Yudkin, P. & Woods, M. (1992) Motivational effect of cholesterol measurement in general practice health checks. *British Journal of General Practice*, **42**, 469–472.
- Rogers, R.W. (1975) A protection motivation theory of fear appeals and attitude change. *Journal of Psychology*, **91**, 93–114.
- Rogers, R.W. (1983) Cognitive and psychological process in fear appeals and attitude change: a revised theory of protection motivation. In *Social Psychophysiology: A Source Book* (ed. by J.T. Cacioppo & R.E. Petty), pp. 153–176. Guilford Press, New York.
- Rogers, R.W. & Prentice-Dunn, S. (1997) Protection motivation theory. In *Handbook of Health Behavior Research* (ed. by D.S. Gochman), pp. 113–132. Plenum, New York.
- Rudkowska, I. & Jones, P. (2007) Functional foods for the prevention and treatment of cardiovascular disease: cholesterol and beyond. *Expert Review of Cardiovascular Therapy*, **5**, 477–490.
- Ruiter, R.A.C., Verplanken, B., Kok, G. & Werrij, M.Q. (2003) The role of coping appraisal in reactions to fear appeals: do we need threat information? *Journal of Health Psychology*, **8**, 465–474.
- Sapp, S.G. & Jensen, H.H. (1998) An evaluation of the health belief model for predicting perceived and actual dietary quality. *Journal of Applied Social Psychology*, **28**, 235–248.
- Sapp, S.G. & Weng, C.-Y. (2007) Examination of the health belief model to predict the dietary quality and body mass of adults. *International Journal of Consumer Studies*, **31**, 189–194.
- Schafer, R., Keith, P. & Schafer, E. (1995) Predicting fat in diet of marital partners using the health belief model. *Journal of Behavioural Medicine*, **18**, 419–433.
- Senior, V. & Marteau, T. (2007) Causal attributions for raised cholesterol and perceptions of effective risk-reduction: self-regulation strategies for an increased risk of coronary heart disease. *Psychology and Health*, **22**, 699–717.
- Shepherd, R. (2006) The use of the stages of change model with dietary behaviours. In *The Psychology of Food Choice* (ed. by R. Shepherd & M. Raats), pp. 345–356. CABI, Wallingford, UK.
- Sorenson, D. & Bogue, J. (2005) Market-oriented new product design of functional orange juice beverages: a qualitative approach. *Journal of Food Products Marketing*, **11**, 57–73.
- Sparks, P., Conner, M., James, R., Shepherd, R. & Povey, R. (2001) Ambivalence about health-related behaviours: an exploration in the domain of food choice. *British Journal of Health Psychology*, **6**, 53–68.
- Strychar, I.M., Champagne, F., Ghadirian, P., Bonin, A., Jenicek, M. & Lasater, T. (1998) Impact of receiving blood cholesterol test results on dietary change. *American Journal of Preventive Medicine*, **14**, 103–110.
- Tanner, J.E., Hunt, J.B. & Eppright, D.R. (1991) The protection motivation model: a normative model of fear appeals. *Journal of Marketing*, **55**, 36–45.
- Tanner, J.F., Day, E. & Crask, M.R. (1989) Protection motivation theory: an extension of fear appeal theory in communication. *Journal of Business Research*, **19**, 267–276.
- Urala, N. & Lahteenmaki, L. (2004) Attitudes behind consumers' willingness to use functional foods. *Food Quality and Preference*, **15**, 793–803.
- Verbeke, W. (2005) Consumer acceptance of functional foods: socio-demographic, cognitive and attitudinal determinants. *Food Quality and Preference*, **16**, 45–57.
- Verbeke, W. & Vackier, I. (2005) Individual determinants of fish consumption: application of the theory of planned behaviour. *Appetite*, **44**, 67–82.
- Weinstein, N.D. (1993) Testing four competing theories of health-protective behaviour. *Health Psychology*, **12**, 324–333.
- Weinstein, N.D., Lyon, J.E., Sandman, P.M. & Cuite, C.L. (1998) Experimental evidence for stages of health behaviour change: the precaution adoption process model applied to home random testing. *Health Psychology*, **17**, 445–453.
- Weinstein, N.N. (2007) Misleading tests of health behaviour theories. *Annals of Behavioral Medicine*, **33**, 1–10.
- Wennstrom, P. & Mellentin, J. (2003) *The Food and Health Marketing Handbook*. New Nutrition Business, London.
- West, G.E., Gendron, C., Larue, B. & Lambert, R. (2002) Consumers' valuation of functional properties of foods: results from a Canada-wide survey. *Canadian Journal of Agricultural Economics*, **50**, 541–558.
- Weststrate, J.A. & Meijer, G.W. (1998) Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. *European Journal of Clinical Nutrition*, **52**, 334–343.
- Wrick, K.L. (1993) Functional foods: cereal products at the food-drug interface. *Cereal Foods World*, **38**, 205–214.